• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    8/14/25 4:15:16 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care
    Get the next $OMDA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Omada Health, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value

    (Title of Class of Securities)


    68170A108

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    Andreessen Horowitz Fund IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,210,602.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,210,602.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,210,602.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    AH Equity Partners IV, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,210,602.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,210,602.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,210,602.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.6 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    AH Parallel Fund IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    403,972.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    403,972.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    403,972.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    AH Equity Partners IV (Parallel), L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    403,972.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    403,972.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    403,972.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    Marc L. Andreessen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,614,574.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,614,574.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,614,574.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    68170A108


    1Names of Reporting Persons

    Benjamin A. Horowitz
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,614,574.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,614,574.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,614,574.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Omada Health, Inc.
    (b)Address of issuer's principal executive offices:

    611 Gateway Blvd, Suite 120, South San Francisco, CA, 94080.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Andreessen Horowitz Fund IV, L.P. ("AH IV") AH Equity Partners IV, L.L.C. ("AH Equity IV") AH Parallel Fund IV, L.P. ("AH Parallel IV") AH Equity Partners IV (Parallel), L.L.C. ("AH Equity Parallel IV") Mark L. Andreessen ("Andreessen") Benjamin A. Horowitz ("Horowitz") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    The address for each of the Reporting Persons is: Andreessen Horowitz 2865 Sand Hill Road, Suite 101 Menlo Park, CA 94025
    (c)Citizenship:

    AH IV Delaware AH Equity IV Delaware AH Parallel IV Delaware AH Equity Parallel IV Delaware Andreessen United States Horowitz United States
    (d)Title of class of securities:

    Common Stock, $0.001 par value
    (e)CUSIP No.:

    68170A108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The Reporting Persons ownership of the Issuer's securities includes (i) 4,210,602 shares of common stock directly held by AH IV; and (ii) 403,972 shares of common stock directly held by AH Parallel IV. AH Equity IV is the general partner of AH IV and may be deemed to have sole power to vote and sole power to dispose of the shares of the Issuer held of record by AH IV for itself and as nominee of Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P. and Andreessen Horowitz Fund IV-Q, L.P. Andreessen and Horowitz are managing members of AH Equity IV and may be deemed to have shared voting and shared dispositive power over the shares held of record by AH IV for itself and as nominee. AH Equity Parallel IV is the general partner of AH Parallel IV and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer held of record by AH Parallel IV for itself and as nominee of AH Parallel Fund IV-A, L.P., AH Parallel Fund IV-B, L.P., and AH Parallel Fund IV-Q, L.P. Andreessen and Horowitz are managing members of AH Equity Parallel IV and may be deemed to have shared voting and shared dispositive power over the shares held of record by AH Parallel IV for itself and as nominee.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 55,744,340 shares of common stock outstanding as of June 9, 2025, as disclosed in the Issuer's prospectus dated June 5, 2025 filed with the Securities and Exchange Commission (the "SEC") on June 9, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited partnership agreements of each of AH IV and AH Parallel IV and the limited liability company agreements of AH Equity IV and AH Equity Parallel IV, the general partner and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or a member, as the case may be.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Andreessen Horowitz Fund IV, L.P.
     
    Signature:/s/ Phil Hathaway
    Name/Title:By AH Equity Partners IV, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 1)
    Date:08/14/2025
     
    AH Equity Partners IV, L.L.C.
     
    Signature:/s/ Phil Hathaway
    Name/Title:By Phil Hathaway, Chief Operating Officer
    Date:08/14/2025
     
    AH Parallel Fund IV, L.P.
     
    Signature:/s/ Phil Hathaway
    Name/Title:By AH Equity Partners IV (Parallel), L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 2)
    Date:08/14/2025
     
    AH Equity Partners IV (Parallel), L.L.C.
     
    Signature:/s/ Phil Hathaway
    Name/Title:By Phil Hathaway, Chief Operating Officer
    Date:08/14/2025
     
    Marc L. Andreessen
     
    Signature:/s/ Phil Hathaway
    Name/Title:By Phil Hathaway, Attorney-in-Fact
    Date:08/14/2025
     
    Benjamin A. Horowitz
     
    Signature:/s/ Phil Hathaway
    Name/Title:By Phil Hathaway, Attorney-in-Fact
    Date:08/14/2025

    Comments accompanying signature:  Note 1: Andreessen Horowitz Fund IV, L.P. for itself and as nominee for Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P. and Andreessen Horowitz Fund IV-Q, L.P. Note 2: AH Parallel Fund IV, L.P. for itself and as nominee for AH Parallel Fund IV-A, L.P., AH Parallel Fund IV-B L.P. and AH Parallel Fund IV-Q, L.P.
    Exhibit Information

    Exhibit 24.1 Power of Attorney for Marc L. Andreessen, dated June 23, 2023. Exhibit 24.2 Power of Attorney for Benjamin A. Horowitz, dated June 22, 2023. Exhibit 99.1 Joint Filing Agreement

    Get the next $OMDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMDA

    DatePrice TargetRatingAnalyst
    7/1/2025$21.00Outperform
    Evercore ISI
    7/1/2025$25.00Overweight
    Morgan Stanley
    7/1/2025$19.00Overweight
    Analyst
    7/1/2025$23.00Buy
    Needham
    7/1/2025$21.00Overweight
    Barclays
    7/1/2025$29.00Buy
    Goldman
    7/1/2025$27.00Buy
    Canaccord Genuity
    More analyst ratings

    $OMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omada Health Reports Second Quarter 2025 Results

    Revenue of $61 million, up 49%52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) --  Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Highlights Total Members of 752,000, up 52% compared to the second quarter of 2024Revenue of $61 million, up 49% compared to the second quarter of 2024GLP-1 Companion Success, with strong growth in members being supported by Omada's GLP-1 companion programs - now available through two of the largest pharmacy benefit managers in the United StatesOmada Horizon Day: In M

    8/7/25 4:05:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

    7/17/25 4:30:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

    SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in

    6/17/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

    8/14/25 4:17:07 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

    8/14/25 4:15:16 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Omada Health Inc.

    10-Q - Omada Health, Inc. (0001611115) (Filer)

    8/8/25 4:16:56 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Omada Health with a new price target

    Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00

    7/1/25 8:41:36 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Morgan Stanley initiated coverage on Omada Health with a new price target

    Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:21:32 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Omada Health with a new price target

    Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00

    7/1/25 8:21:32 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hilleman Jeryl L was granted 376 shares, increasing direct ownership by 4% to 10,112 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 5:18:11 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Root Jonathan D was granted 237 shares, increasing direct ownership by 2% to 9,973 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 4:15:30 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Fetter Trevor was granted 257 shares, increasing direct ownership by 3% to 9,993 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 4:14:24 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Financials

    Live finance-specific insights

    View All

    Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

    7/17/25 4:30:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

    SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in

    6/17/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care